Dear Editor:

# Please find enclosed my/our manuscript entitled “Importance and Risk Prediction of ABO Blood Group and Rh Factor in Papillary Thyroid Cancer,” which I/we request you to consider for publication as Journal of Endocrinology Research.

Thyroid cancers are one of the most common endocrine malignancy. Approximately 85% of differentiated thyroid cancers are papillary thyroid cancers (PTCs). Clinical studies have shown that ABO blood type plays a role in various diseases, including malignancies. However, the studies reporting the association between blood type and cancer have often reported conflicting results, and ***there*** is limited data in the literature regarding the potential relationship between thyroid cancer and ABO blood types and Rh factor. Further, the prognostic significance of this relationship in patients with PTC remains ambiguous. We aimed to investigate whether PTC is associated with blood type.For this, we included patients diagnosed with PTC via histopathological analysis (PTC group) and control individuals (control group) whose blood type was analyzed at a random blood center. The median ages of both the control and PTC groups were same, i.e., 43 years. A comparison of patients based on ABO blood types and Rh factor revealed that A Rh positive blood type was observed 31% less frequently in the PTC group compared with the control group, and thus it was associated with a lower risk of PTC. Hence, A Rh positive blood type was significantly less frequent among patients with PTC. Although the O Rh positive blood type was detected at a higher rate in patients with PTC, no statistically significant difference was noted compared with the other blood types. In conclusion, A Rh positive blood type can be considered as a favorable marker suggesting a reduced risk of PTC.

This manuscript has not been published elsewhere and is not under consideration by another journal. I/We have approved the manuscript and agree with submission to Journal of Endocrinology Research. There are no conflicts of interest to declare.

This study was approved by Dicle University medical ethics committee (No:145/2021) in accordance with the ethical standards of the Declaration of Helsinki.

I/We believe that the findings of this study are relevant to the scope of your journal and will be of interest to its readership. The manuscript has been carefully reviewed by an experienced editor whose first language is English and who specializes in editing papers written by scientists whose native language is not English.

I/We look forward to hearing from you at your earliest convenience.

Sincerely,

Dilek GENEŞ (corresponding author\*)

Dicle University Faculty of Medicine, Department of Adult Endocrinology and Metabolism/ Diyarbakir/ Turkey 21090

Phone No: +90 5070664022

Email Address: dilekgenes21mail.com

Authors:

*Dilek Geneş\*1, Zafer Pekkolay1, Mehmet Şimşek1, Hüsna Saraçoğlu1, Mehmet Turgut1, Alpaslan Kemal Tuzcu1*

1Dicle University Faculty of Medicine, Department of Adult Endocrinology and Metabolism/ Diyarbakir/ Turkey

# Instructions for Author (Please delete this section before submission)

We have gone through your manuscript in detail and prepared a customized cover letter for you. There may be some information that you need to add to the cover letter. We have inserted some comments in the cover letter for your perusal. Enago will review the cover letter for free (after your changes) under our Manuscript Insurance service or our Question and Answer Service.

**Additional Notes:**

1. DATE

Please change the date to the date on which you will submit the paper. Use the British (dd/mm/yy) or the American (mm/dd/yy) format as per the target journal.

1. GRANT

In case your study is funded by a particular institute or association and you would like to mention this in the cover letter, please add the following sentence.

"The study was supported by a grant from the [GRANT DETAILS]."

1. CONFLICT OF INTEREST

In case there is a conflict of interest, please provide the appropriate information in place of "There are no conflicts of interest to declare."